Intomics and AstraZeneca partner to accelerate drug discovery initiatives through data mining. AstraZeneca’s knowledge within a range of diseases will be combined with Intomics’ unique data analysis services to improve drug discovery projects.

AstraZeneca and Intomics have signed an agreement to accelerate drug discovery programs via Intomics’ advanced, tailor-made solutions. With the collaboration announced today, AstraZeneca gains access to Intomics’ pioneering knowledge discovery capabilities as well as leading expertise within the fields of biological data analysis, bioinformatics and systems biology. Intomics is going to assists in drug discovery projects by providing data, methods, and tools for integrating and analysing highly complex proprietary clinical, biological and chemical data. The collaboration spans a range of research projects. The financial terms of the agreement were not disclosed.

“We are delighted to assist AstraZeneca with their very exciting research projects. We see a great synergy in combining our data analysis expertise with AstraZeneca’s profound knowledge in some very important disease areas.  The collaboration will help facilitate efficient drug discovery projects with shorter turnaround time and improved results,” says Thomas S. Jensen, CEO of Intomics. He continues, “With the huge amount of data generated in today’s research projects, access to leading data analysis capabilities becomes key, and we are pleased that AstraZeneca, one of the largest pharmaceutical companies in the world, has recognized our expertise within the field.”